丙戊酸治疗对癫痫儿科患者体重增加的影响。
The impact of valproic acid treatment on weight gain in pediatric patients with epilepsy.
机构信息
Catholic University Medical School, Institute of Pediatrics, Rome, Italy -
Service of Pediatrics, Campus Bio-Medico University, Rome, Italy -
出版信息
Minerva Pediatr (Torino). 2022 Aug;74(4):408-411. doi: 10.23736/S2724-5276.17.04938-6. Epub 2017 Jun 22.
BACKGROUND
Valproic acid (VPA) is an antiepileptic drug, used for focal and generalized seizure. VPA treatment resulted in significant weight gain but there are no systematic data about the prevalence of this side effect. The aim of the study was to evaluate the weight gain of a pediatric population with epilepsy.
METHODS
We enrolled 38 patients, 17 females and 21 males with a mean age of 8.2±4.4 years. We evaluated data about height, weight and BMI at beginning of treatment and at 24, 36 and 48 months of follow-up.
RESULTS
There is a statistically significant difference between the percentile value of weight and BMI at baseline and at 36 and 48 months of follow-up (P<0.01) but there is not statistically significant difference between the percentile value of height (P=0.22 and P=0.18).
CONCLUSIONS
We believe that a nutritional support should be guaranteed to the pediatric patients with epilepsy that begin the VPA therapy.
背景
丙戊酸（VPA）是一种抗癫痫药物，用于治疗局灶性和全面性癫痫发作。VPA 治疗会导致明显的体重增加，但目前尚无关于这种副作用发生率的系统数据。本研究旨在评估癫痫患儿的体重增加情况。
方法
我们招募了 38 名患者，其中 17 名女性和 21 名男性，平均年龄为 8.2±4.4 岁。我们评估了治疗开始时以及随访 24、36 和 48 个月时的身高、体重和 BMI 数据。
结果
体重和 BMI 的百分位值在基线时与随访 36 和 48 个月时存在统计学差异（P<0.01），但身高的百分位值没有统计学差异（P=0.22 和 P=0.18）。
结论
我们认为，开始 VPA 治疗的癫痫儿科患者应获得营养支持。
Zotero 插件